Prodencel - Shanghai Humantech Biotechnology
Alternative Names: Autologous dendritic cell therapeutic tumour vaccine - Shanghai Humantech Biotechnology; ProdencelLatest Information Update: 20 Sep 2022
At a glance
- Originator Shanghai Humantech Biotechnology
- Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 08 Aug 2022 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in China (SC) (NCT05533203)